These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 33211395)

  • 1. Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study.
    Wang H; Zhao Y; Zhang X; Si X; Song P; Xiao Y; Yang X; Song L; Shi J; Zhao H; Zhang L
    Cancer Med; 2021 Jan; 10(1):188-198. PubMed ID: 33211395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical and chest CT features of immune checkpoint inhibitor-related pneumonitis].
    Zhang Q; Zhao SJ; Wang SH; Tao XL; Wu N
    Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):182-187. PubMed ID: 36781241
    [No Abstract]   [Full Text] [Related]  

  • 3. Cytomegalovirus infection as an underestimated trigger for checkpoint inhibitor-related pneumonitis in lung cancer: a retrospective study.
    Lin X; Lu T; Li S; Xie X; Chen X; Jiang J; Qin Y; Xie Z; Liu M; Ouyang M; Zhong N; Song Y; Zhou C
    Clin Transl Oncol; 2021 Feb; 23(2):389-396. PubMed ID: 32613413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
    Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X
    BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Manifestation, Risk Factors, and Immune Checkpoint Inhibitor Rechallenge of Checkpoint Inhibitor-Associated Pneumonitis in Patients With Lung Cancer.
    Li X; Yang F; Liu B; Ye L; Du J; Fan X; Yu Y; Li M; Bu L; Zhang Z; Xie L; Li W; Qi J
    J Immunother; 2024 Jul-Aug 01; 47(6):220-226. PubMed ID: 38618919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Characteristics, Management and Prognostic Factors of Immune Checkpoint Inhibitor-Associated Pneumonia in Chinese Cancer Patients.
    Li J; Chen S; Yan T; Zeng M
    J Coll Physicians Surg Pak; 2024 Mar; 34(3):302-307. PubMed ID: 38462865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer.
    Moda M; Saito H; Kato T; Usui R; Kondo T; Nakahara Y; Murakami S; Yamamoto K; Yamada K
    Thorac Cancer; 2020 Dec; 11(12):3576-3584. PubMed ID: 33078531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The application of bronchoscopy in the assessment of immune checkpoint inhibitor-related pneumonitis severity and recurrence.
    Guo C; Zhang Q; Zhou P; Cheng Y; Nie L; Wang G
    Sci Rep; 2024 Jul; 14(1):17137. PubMed ID: 39060280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical features and prognostic analysis of checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer].
    Chen RX; Liu XN; Xu Y; Shi YJ; Wang MQ; Shao C; Huang H; Xu K; Wang MZ; Xu ZJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Mar; 47(3):207-213. PubMed ID: 38448169
    [No Abstract]   [Full Text] [Related]  

  • 10. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.
    Tone M; Izumo T; Awano N; Kuse N; Inomata M; Jo T; Yoshimura H; Minami J; Takada K; Miyamoto S; Kunitoh H
    Thorac Cancer; 2019 Oct; 10(10):2006-2012. PubMed ID: 31482678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study.
    Tiu BC; Zubiri L; Iheke J; Pahalyants V; Theodosakis N; Ugwu-Dike P; Seo J; Tang K; Sise ME; Sullivan R; Naidoo J; Mooradian MJ; Semenov YR; Reynolds KL
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis.
    Park C; Keam B; Yoon SH; Ock CY; Choi SM; Kim M; Park YS; Kim TM; Oh DY; Kim DW; Kim YW; Heo DS; Bang YJ
    ESMO Open; 2019; 4(6):e000575. PubMed ID: 31803501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and therapeutic effects of checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
    Pang L; Xie M; Ma X; Huang A; Song J; Yao J; Deng H; Zhang D; Zang X; Ren F; Gao J; Wu C; Wang Y; Zhang X; Bao X; Pan L; Xue X
    BMC Cancer; 2023 Mar; 23(1):203. PubMed ID: 36869304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer.
    Tao H; Li F; Wu D; Ji S; Liu Q; Wang L; Liu B; Facchinetti F; Leong TL; Passiglia F; Hu Y
    Transl Lung Cancer Res; 2022 Mar; 11(3):381-392. PubMed ID: 35399572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease.
    Zeng Z; Qu J; Yao Y; Xu F; Lu S; Zhang P; Yao Y; Li N; Zhou J; Wang Y
    BMC Pulm Med; 2022 Dec; 22(1):458. PubMed ID: 36456932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors.
    Shibata Y; Murakami S; Kato T
    Expert Opin Drug Saf; 2021 May; 20(5):537-547. PubMed ID: 33650443
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Cancer Patients: A Systemic Review and Meta-Analysis.
    Zhou P; Zhao X; Wang G
    Respiration; 2022; 101(11):1035-1050. PubMed ID: 36108598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1
Antibody-Safety and Effectiveness of Pirfenidone].
    Yu H; Li J; Yu L; Cheng X; Han X; Zhang X
    Zhongguo Fei Ai Za Zhi; 2021 Jul; 24(7):519-525. PubMed ID: 34134189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina.
    Atchley WT; Alvarez C; Saxena-Beem S; Schwartz TA; Ishizawar RC; Patel KP; Rivera MP
    Chest; 2021 Aug; 160(2):731-742. PubMed ID: 33621599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
    Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
    J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.